Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of July 2025, with a report date of July 18, 2025. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific share acquisition transactions.
| Transaction Date | Instrument | Price per ADS | Total Volume (ADSs) | Exchange |
|---|---|---|---|---|
| 2025-07-17 | American Depositary Shares (ADSs) | $38.1181 | 4,492.051 (Aggregate) | New York Stock Exchange (XNYS) |
Note: The aggregate volume represents the sum of three separate transactions executed by different individuals at the same price.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine acquisitions of ADSs by three executives following the re-investment of dividends paid to shareholders on July 10, 2025.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a statutory disclosure of specific share transactions.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of ADSs resulting from dividend re-investment plans, not open-market purchases.
- Participants: Transactions were executed by Dr. Hal Barron (Non-Executive Director), James Ford (SVP and Group General Counsel), and Shobie Ramakrishnan (Chief Digital and Technology Officer).
- Market Price: The ADS price at the time of transaction was $38.1181.
- Dividend Context: The transactions were triggered by dividends paid on July 10, 2025.